Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Exercise Therapy Recommended to Manage Knee Osteoarthritis

Allyn Bove, PT, DPT, & G. Kelley Fitzgerald, PT, PhD, FAPTA  |  July 12, 2016

The benefits of exercise therapy for individuals with knee osteoarthritis (OA) are well known. The ACR strongly recommends both aquatic exercise and land-based aerobic and resistance exercise for managing knee OA.1 A recent Cochrane systematic review and meta-analysis concluded that high-quality evidence supports the use of exercise to reduce pain and improve physical function and…

Rheumatology Drug Updates: Labeling for Fluoroquinolones; FDA to Review Benzhydrocodone/Acetaminophen Combination

Michele B. Kaufman, PharmD, BCGP  |  July 12, 2016

FDA Restricts Fluoroquinolone Use The U.S. Food and Drug Administration (FDA) has twice previously communicated safety information about systemic fluoroquinolones—in August 2013 and July 2008. The safety issues of this medication class described in its latest Drug Safety Communication were also discussed at a November 2015 FDA Advisory Committee meeting.1 The FDA is now advising…

Rheumatologists on the Move, July 2016

Ann-Marie Lindstrom  |  July 12, 2016

HSS Holds First Rheumatology Gala The Hospital for Special Surgery (HSS) in New York City hosted a Rheumatology Gala in May. The event, held at The Park Avenue Armory in Manhattan, was held to increase awareness of HSS’s leading research and treatment of rheumatic diseases—particularly with “high-net worth people,” according to former ACR President Mary…

Rheumatologist Dr. Jonathan Coblyn Releases Stress by Fishing

Carol Patton  |  July 12, 2016

Jonathan Coblyn, MD, was around 10 years old the first time his father took him fishing in April to Great South Bay, the largest shallow saltwater bay in New York. It was so cold that he remembers scraping frost off the lines that tied the family’s 26-foot motorboat to the pier. Dr. Coblyn, clinical chief…

Practicing Telemedicine Raises Legal Considerations for Rheumatologists

Steven M. Harris, Esq.  |  July 12, 2016

With the evolution and advancement of technology, it was only a matter of time before such changes affected the medical industry. Although the concept of telemedicine dates back more than 50 years, emphasis on cost-effective quality healthcare coupled with technological advancements has caused a resurgence of telemedicine in recent years. What constitutes telemedicine largely depends…

Medical Marijuana's Potential Benefits, Risks

Medical Marijuana’s Potential Benefits, Risks

Thomas R. Collins  |  July 12, 2016

CHICAGO—Despite the complicated politics surrounding medical marijuana, cannabis has a wide variety of medical benefits and potential benefits, but the risks need to be understood, said Daniel Clauw, MD, director of the Chronic Pain and Fatigue Research Center at the University of Michigan, in a session at the ACR’s 2016 State-of-the-Art Clinical Symposium. Effects It’s…

Lupus Expert Calls for Better Research, Outcomes of Clinical Trials

Thomas R. Collins  |  July 12, 2016

CHICAGO—A lupus expert recently issued a call for action to improve outcomes of lupus clinical trials, a field that has had so many failed potential therapies that he said it seems to be “cursed.” Richard Furie, MD, chief of rheumatology at Northwell Health in New York, said at the ACR’s 2016 State-of-the-Art Clinical Symposium that…

3D Printing in Rheumatology Holds Promise for External Devices, Joints

3D Printing in Rheumatology Holds Promise for External Devices, Joints

Bryn Nelson, PhD  |  July 11, 2016

When Abby Paterson, PhD, started her doctoral work in product design and technology at Loughborough University in the United Kingdom in 2009, she says 3D printing was little known by clinicians or the general public. Now, the technology is seemingly everywhere. For Dr. Paterson, the advancing science has led to a promising project focused on…

Rheumatology Case Report: Concomitant Lupus with Features of Scleroderma, Castleman Disease

Kwabna Parker, MBBS, Sireesha Datla, MD, & Nancy Soloman, MD  |  July 11, 2016

We report a case of a 27-year-old woman who was initially diagnosed with systemic lupus erythematosus (SLE), had features of scleroderma and was subsequently found to have lymph node biopsy consistent with multicentric Castleman disease (MCD). She also had serologic evidence of acute Epstein-Barr virus (EBV) infection (vs. reactivation of EBV). The occurrence of MCD…

Conformational Flexibility in HLA-B27 Provides Clues to Development of Ankylosing Spondylitis

Kathy Holliman  |  July 11, 2016

Understanding how human leukocyte antigen (HLA) class I molecule B27 promotes spondyloarthritis has intrigued researchers for four decades. Although the association between the single gene variant HLA-B27—specifically some of its subtypes—with ankylosing spondylitis (AS) is particularly strong, how HLA-B27 directly influences disease development has not yet been clearly explained, although hypotheses continue to be generated….

  • « Previous Page
  • 1
  • …
  • 492
  • 493
  • 494
  • 495
  • 496
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences